Page values for "Insulin Glargine"

Nav

"Medicines" values

1 row is stored for this page

Field	Field type	Value
generic	`String`	Insulin glargine
brand	`String`	Lantus, Basaglar, Semglee, Toujeo (U-300)
structure	`File`
classes	List of `String`, delimiter: `,`	[[:Category:Insulins\|Insulin]] • [[:Category:Long-acting_insulins\|Long-acting insulin analog]] • [[:Category:Basal_insulins\|Basal insulin]]
mechanism	`String`	'"`UNIQ--vote-00000237-QINU`"' Binds the same insulin receptor as endogenous insulin with comparable mitogenic-to-metabolic ratio; provides basal hepatic glucose suppression and peripheral glucose uptake without prandial peaks'"`UNIQ--ref-00000238-QINU`"'.
uses	`String`	'"`UNIQ--vote-00000239-QINU`"', '"`UNIQ--vote-0000023A-QINU`"'
starting_dose	`String`	~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose
preparations	`String`	100 U/mL (Lantus, Basaglar, Semglee) vials and pens; 300 U/mL (Toujeo) pens
fda_max	`String`	Titrated to glucose; no fixed ceiling
pill_id	`Text`
routes	List of `String`, delimiter: `,`	Subcutaneous (never IV; not for use in insulin pumps)
onset	`String`	1-2 hours
duration	`String`	~24 hours per dose (peakless profile by design)
halflife	`String`	~12 hours apparent (functional duration ~24 hours due to depot release kinetics)'"`UNIQ--ref-0000023B-QINU`"'
bioavailability	`String`	~100% from subcutaneous depot (by definition of the route)
pregnancy	`String`	Insulin is the preferred glucose-lowering therapy in pregnancy; glargine has reassuring observational data, though NPH and detemir remain the traditional choices.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed\|citation needed]]]</sup>
legal	`String`	[[USLegal:Prescription only\|Rx-only]] in US